Download the Case Study
A Pivotal Phase III Trial for a New Class of Antibiotic for the Treatment of Uncomplicated UTIs
A Pivotal Phase III Trial for a New Class of Antibiotic for the Treatment of Uncomplicated UTIs
Strategic Approaches to Achieving Rapid Site Start-Up and FDA Approval in a Phase III UTI Study
In a newly released case study, Medpace experts explore strategic approaches to achieving rapid site start-up and FDA approval in Urinary Tract Infection (UTI) trials.
In this Phase III registrational trial for a new class of antibiotic for the treatment of uncomplicated UTIs, Medpace was able to surpass the site activation goal, complete enrollment ahead of schedule, and achieve regulatory goals.
Your Next Breakthrough Starts Here
Leading Infectious Diseases & Vaccines CRO
The complex and dynamic nature of infectious diseases demands an experienced CRO partner with deep medical expertise across various indications. Medpace’s specialized cross-functional team of experts have extensive experience executing global trials in antivirals, antibacterials, antifungals, vaccines, and immunotherapies spanning adult and pediatric patients, as well as special at-risk populations. Our experienced medical leadership team, integrated laboratories, clinical trial management system, and extensive site and investigator relationships produce a truly seamless drug development process.
